Remove 2027 Remove Pharmaceutical Remove Sourcing
article thumbnail

Revolutionizing Skin Repair with Recombinant Type XVII Collagen in China’s Growing Markets

Frost & Sullivan Manufacturing

billion CNY in 2027. billion CNY in 2027. billion CNY in 2027. billion by 2027. billion by 2027. Trautec, with large-scale, eco-friendly production of collagen types I, II, III, and XVII SRHC, has expanded globally, securing partnerships with 30+ cosmetic and pharmaceutical leaders. in 2017 to 18.5%

article thumbnail

Aduro Clean Technologies Files New Patent Application to Transform Waste Plastics and Renewable Oils into High Value BTX Chemicals

i4.0 today

BTX compounds are essential building blocks for a wide array of high-value chemicals and materials, including plastics, paints, sealants, coatings, and pharmaceuticals. billion by 2027. Aromatic chemicals like BTX are key building blocks, accounting for 40% of petrochemical production by volume.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Fusing biology with the bionic ear

E&T

These cells are like ‘keys on a piano’ and range from low to high frequency, explains Dr Robert Gay, director of pharmaceutical approaches at Cochlear, a Sydney-based manufacturer of the device. Three-and-a-half-thousand acoustic hair cells in the inner and outer cochlea convert vibration of sound into an electrical signal into the brain.

article thumbnail

ABB to Invest $280 million in Its European Robotics hub in Sweden

Fabricating & Metal Work

With the facility, ABB will expand production capacity by 50 percent and strengthen its capabilities to supply the European market, which is expected to grow at seven percent CAGR through 2027 1. Source: Interact Analysis www.abb.com go.abb/robotics Subscribe to learn the latest in manufacturing.

article thumbnail

Sanofi Canada to invest $180M to update infrastructure and reduce emissions across its mfg. operations

Canadian Manufacturing

This investment is in addition to a $2-billion CAD joint investment with governments at all levels at our Toronto Campus to build two new state-of-the-art vaccine manufacturing facilities by 2027.”

article thumbnail

Top Legal Issues Facing the Manufacturing Sector in 2023

Foley

Companies that may be concerned about the viability or performance of a supplier should consider seeking licenses or other rights that would enable to obtain vital components from another source if the supplier does not meet its obligations. Healthcare and Pharmaceuticals. This directive is not limited to supply contracts alone.